FHC Colorectal Mucosal Cells (FHC)

Colorectal cancer (CRC) is a very common gastrointestinal malignant tumor for which the incidence is increasing annually and the age at diagnosis is becoming younger. At present, surgical resection is mainly used in clinical practice, supplemented by preoperative or postoperative chemotherapy. Although CRC diagnosis and treatment methods have made significant progress, due to the hidden onset of colon cancer, most patients have already reached the middle or late stage at the time of diagnosis. The shortage of sensitive analytical methods to diagnose CRC in the early stage leads to poor prognosis and around more than half of the patients with a continuous progression eventually die due to metastasis and recurrence. Molecularly targeted therapeutic drugs have recently played a significant role in the comprehensive treatment of patients with advanced CRC. Molecularly targeted therapeutic drugs with different targets have different effects, but the clinical application of molecularly targeted drugs is still unclear. There are many problems that need to be further clarified. For that reason, the discovery of molecular targets for early detection and novel targets for treatment, as well as the identification of molecular pathways impacting the growth of CRC, are crucial.